Prices of medicines have gone down in the Netherlands for the last 20 years. The issue of pricing demonstrates how the different stakeholders in care keep each other as prisoner in the same context, rather than as co-stakeholder to the same goal: realizing better care to a lesser cost. Surely a provider of drugs can be hold at a distance to the other stakeholders, suggesting the pharma industry can be overpowered by payers, politicians or other stakeholders. It is a short sighted attitude. Innovation in care cannot do without close collaboration between stakeholder and a common way in dealing with costs and profits.
As doctors do use “mobile” devices now dominantly to get their information about new developments, the industry needs to adapt their way of informing their clients. Edetailing for the health industry is the norm, not a futuristic issue any more. Edetailing is not just about presenting information. It should also direct the industry’s ways of interaction with its clients. And, more so, to acknowledge that the end goal lies not just in using drugs or devices, but in improving care. That triggers fundamental change of how the industry needs to relate with its customers.
Health care trend of trends 2014?
What have been named as trends in health care development for 2014?
Reviewing several blogs, these I came to mention:
1. Financial concerns;
2. Patient empowerment;
3. Connected health, eHealth;
4. Redefining the health industry and
5. Data security.
Is that what it is? No, we should look at what “the” trend in health care development should be. See for that part 2.
Russian Conditions to the health care market – How could the industry adapt?
This spring, I was as lucky to be invited to the Russian Pharmaceutical Phorum, May 23rd, in St. Petersburg.
As there is a lot to develop in the Russian health care system, there are lots of opportunities how the health industry might help out. However, they need to change their view on approach of the market from sales to partner in care. Russian markets, however still growing, will be careful in spending money. And, when you only sell medicine, your business coincides with the price of your product. But when you work together with stakeholders to care for patients you might be a collaborator and your value will go beyond your product’s price.
John Mack, better known as @Pharmaguy from Pharma Marketing news asked me to have an interview with me about this new commercial model for pharma, working customer centric.
Here’s the interview. Having no transcript, I added my pre-interview notes.